Exhibit 10.33


 


Addendum
Number 4 of the “Up to USD 

150,000.00 Credit Facilites Agreement”


 


 


“Addendum”


 


of


 


 8
January 2021


 


between


 


 


NLS Pharmaceutics Ltd.


Alter Postplatz


6370 Stans


	Switzerland	“Borrower”



 


 


and


 



 


	Ronald Hafner	 	 
	  



	 	“Lender 1”
	 	 	 
	Jürgen Bauer	 	 
	  



	 	“Lender 2”
	 	 	 
	Peter Ödman	 	 
	  



	 	“Lender 3”
	 	 	 
	Michael Stein	 	 
	  



	 	“Lender 4”



 


 


(Lender 1, Lender
2, Lender 3 and Lender 4


the “Lenders”)


 


(Borrower and Lenders
each a “Party”


collectively the “Parties”)


 


 


regarding


current
situation and outstanding amount


 






     


    	Addendum	2/3



    

 


WHEREAS


 


		A.	The Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss law with
its registered seat and principal place of business at Stans (Company Number CHE-447.067.367). The Company has a share capital
of CHF 139’200.00, divided into 6’960’000 registered shares with a nominal value of CHF 0.02 each, which
have been fully paid in.



 


		B.	The Lenders and the Borrower (formerly NLS Pharma AG) entered into the “Up to USD 150,000.00
Credit Facilities Agreement” dated 31 August 2015, as amended on 16 September 2019, on 3 February and in October 2020 (“Agreement”).
The Lenders agreed to make available to the Borrower credit facilities in the aggregate amount of USD 150,000.00 (“Total
Credit Facility Amount”).



 


		C.	The Lenders granted to the Borrower the Total Credit Facility Amount under the Agreement.



 


		D.	According to section 6.1 of the Agreement, the loans under Total Credit Facility Amount shall bear
regular interest at the rate of 0% per annum, calculated from (and including) the day of its drawdown to (and including) the Maturity
Date (or the date of its earlier repayment).



 


		E.	According to section 6.2 of the Agreement, default interest rate of 5% per annum shall apply, in
case the Borrower does not make any payment on the due date as foreseen in the Agreement.



 


		F.	The maturity date for the repayment of the Total Credit Facility Amount together with the accrued
interest was set at 31 December 2020 (“Maturity Date”).



 


NOW,
THEREFORE, the Parties agree as follows:


 


Any capitalized terms, if not defined otherwise
in this Addendum, shall have the meaning as set forth in the Agreement.


 


		1.	Open Amount



 


The Parties hereby confirm
that the Total Credit Facility Amount has not been repaid to the Lenders by the Borrower.


 


		2.	Extension Maturity Date



 


The Maturity Date as set forth
in section 5 of the Agreement shall be extended from 31 December 2020 to 31 March 2021.


 


		3.	Governing Law and Jurisdiction



 


This Addendum shall be governed
by and construed in accordance with the substantive laws of Switzerland, without reference to principles of conflict of laws or
choice of laws.


 


All disputes arising out of
or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall
be resolved by the ordinary courts in Stans (NW), Switzerland.


 


 


[Signature page to follow]


 






     


    	Addendum	3/3



    

 


Borrower


NLS Pharmaceutics Ltd.


 


	/s/ Ronald Hafner	 	/s/ Alexander Zwyer
	Ronald Hafner

        Chairman of
        the Board
	 	Alexander Zwyer

        Chief Executive
        Officer

	 	 	 
	 	 	 


Lenders


 


	/s/ Ronald Hafner	 	/s/ Jürgen Bauer
	Ronald Hafner
	 	Jürgen
        Bauer

	 	 	 
	/s/ Peter Ödman 	 	/s/ Michael Stein 
	Peter Ödman
	 	Michael Stein